Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29704434 | 1.00 | CREBBP (0.34) | CREBBPGRM7KDRTP53PIP4K2A | |
| SCHEMBL21259462 | 0.78 | — | — | |
| SCHEMBL29958362 | 0.77 | CREBBP (0.34) | CREBBPKDRTP53TRPV1 | |
| SCHEMBL15011334 | 0.77 | CREBBP (0.34) | CREBBPKDRTP53TRPV1 | |
| SCHEMBL10310477 | 0.76 | TP53 (0.39) | CREBBPGRM7KDRTP53PIP4K2A | |
| SCHEMBL26517162 | 0.74 | CCR4 (0.37) | CREBBPGRM7TP53PIP4K2A | |
| SCHEMBL23634875 | 0.73 | GRM7 (0.34) | CREBBPGRM7KDRTP53PIP4K2A | |
| SCHEMBL21608562 | 0.73 | PI4KA (0.38) | CREBBPGRM7TP53 | |
| SCHEMBL13676392 | 0.73 | PIP4K2A (0.38) | CREBBPGRM7KDRTP53PIP4K2A | |
| SCHEMBL30861058 | 0.73 | PI4KA (0.38) | CREBBPGRM7TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365335-B1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| CN-115551500-A | 4-aminobut-2-enamide derivatives and salts thereof | 大鹏药品工业株式会社 | 2022-12-30 | — | — | CN | disclosed |
| EP-4067347-A1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3464270-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021085653-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-06 | — | — | WO | disclosed |
| EP-3365335-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | Array Biopharma, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| WO-2017070708-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-2459547-B1 | HERBICIDALLY ACTIVE HETEROARYL-SUBSTITUTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120202691-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | KRAS, NRAS, HRAS | CREBBP 385/4885GRM7 3727/4885KDR 1402/4885 |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | CREBBP 2671/4885GRM7 861/4885KDR 2762/4885 |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR2, FGFR3 | CREBBP 3198/4885GRM7 2819/4885KDR 74/4885 |
| US-20120202691-A1 | NOVEL HERBICIDES | DDT, HCN1, HDHD5 | CREBBP 4790/4885GRM7 540/4885KDR 4498/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CREBBP 6/4885GRM7 3534/4885KDR 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.